Welcome

BioInvent is a research-based pharmaceutical company developing innovative antibody drugs to target diseases with unmet clinical need. The Company's pipeline currently includes product candidates for the treatment of cancer, thrombosis and atherosclerosis.

Capital Markets Day

Link to webcast and presentations »

Meet us

Carnegie Nordic Healthcare Seminar, 21 mars 2012, Stockholm
Kempen Life Science Conference, 22 mars 2012, Amsterdam

Our Pipeline

BioInvent develops antibody-based drugs to tackle conditions where there is a significant need for new treatments. We currently have four antibody therapeutics in development. Find out more »

Press Releases

Latest Share Price

Clinical Trials

BioInvent is currently running a number of early-stage clinical trials with several of its products. Click here to find out more »